Al­ler­gan scores an FDA OK for a new drug tar­get­ing night-time uri­na­tion

Al­ler­gan has scored a new drug ap­proval. But don’t feel bad if you missed the news late last week. This has been a low-pro­file de­vel­op­ment ef­fort with a long stretch in late-stage de­vel­op­ment.

Al­ler­gan signed a com­mer­cial­iza­tion deal with Seren­i­ty Phar­ma­ceu­ti­cals back in 2010 for SER-120, a nasal spray ther­a­py de­vel­oped to treat a con­di­tion known as noc­tur­nal polyuria, the over­pro­duc­tion of urine at night which can in­ter­rupt sleep with too many trips to the toi­let. The FDA signed off on the ap­proval on Fri­day, set­ting up a launch for this drug as Noc­ti­va.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.